Why Poseida Therapeutics Almost Doubled Today, Here Are 75 …

Aug 3, 2022 · Poseida Therapeutics, Inc. (NASDAQ:PSTX) shares jumped 99.6% to $4.85 as the company entered into a strategic collaboration and license agreement with Roche Holdings …

CouponFollow Extension

6%
OFF

Why Poseida Therapeutics Almost Doubled Today, Here Are 75 …

2 days from now

Aug 3, 2022 · Poseida Therapeutics, Inc. (NASDAQ:PSTX) shares jumped 99.6% to $4.85 as the company entered into a strategic collaboration and license agreement with Roche Holdings …

businessinsider.com

6%
OFF

Why Poseida Therapeutics Almost Doubled Today, Here Are 75 …

2 days from now

Aug 3, 2022 · Why Poseida Therapeutics Almost Doubled Today, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session ... Poseida Therapeutics, Inc. PSTX shares jumped 99.6% to …

benzinga.com

$0.32
OFF

Poseida Therapeutics (PSTX) News Today - MarketBeat

2 days from now

Nov 15, 2024 · Poseida Therapeutics (NASDAQ:PSTX - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.32) earnings per share for the quarter, …

marketbeat.com

70%
OFF

Why Poseida Therapeutics Almost Doubled Today, Here… - Inkl

2 days from now

Aug 3, 2022 · Kintara Therapeutics, Inc. (NASDAQ:KTRA) gained 70% to $0.3013 after the company entered into an equity purchase agreement with Lincoln Park Capital for up to $20 …

inkl.com

$1
OFF

Why Poseida Therapeutics Shares Are Trading Higher By… - Inkl

2 days from now

1 day ago · Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal. …

inkl.com

$50
OFF

Why Are Poseida Therapeutics Shares Moving Higher Today?

2 days from now

Aug 7, 2023 · Poseida Therapeutics Inc PSTX shares are trading higher after the company received a $50 million strategic investment by Astellas Pharma Inc ALMPY ALMPF.. The …

benzinga.com

70%
OFF

Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% In One Week

2 days from now

Nov 12, 2024 · Over the past quarter, shares of Poseida Therapeutics, Inc. Have risen 25.34%, and are up 76.67% in the last year. On the other hand, the S&P 500 has only moved 12.69% …

nasdaq.com

82%
OFF

Poseida Therapeutics, Inc. (PSTX) Hit A 52 Week High, Can The Run ...

2 days from now

17 hours ago · For the current fiscal year, Poseida Therapeutics is expected to post earnings of -$1.03 per share on $148.38 million in revenues. This represents a 24.82% change in EPS on …

zacks.com

$20
OFF

Where Poseida Therapeutics Stands With Analysts - Nasdaq

2 days from now

Nov 15, 2024 · In the assessment of 12-month price targets, analysts unveil insights for Poseida Therapeutics, presenting an average target of $20.0, a high estimate of $20.00, and a low …

nasdaq.com

$0.21
OFF

Poseida Therapeutics, Inc. (PSTX) Q3 Earnings And Revenues Beat ...

2 days from now

Nov 7, 2024 · Poseida Therapeutics, Inc. (PSTX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to …

nasdaq.com

FAQs about Why Poseida Therapeutics Almost Doubled Today, Here Are 75 … Coupon?

Did poseida Therapeutics report pipeline Progress at its virtual R&D day?

The biotech reported pipeline progress at its virtual R&D Day. Shares of Poseida Therapeutics (NASDAQ:PSTX) were jumping 21.2% higher as of 12:08 p.m. EST on Wednesday. The big gain came with the company providing a pipeline update at its virtual R&D Day today. ...

What did poseida Therapeutics do in the first quarter?

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2024. ...

Is poseida Therapeutics (PsTx) a real deal?

Poseida Therapeutics (NASDAQ: PSTX) is a cell-therapy-focused biotech that I covered with some optimism back in December 2023, with the company's pipeline showing early signs of being the real deal. ...

Is poseida Therapeutics a good investment for myeloma patients?

Poseida Therapeutics shows promising early results in myeloma with their BCMA-directed allogeneic CAR T-cell therapy, achieving a 60% response rate in phase 1 trials. Financially stable with $30.5 million in cash, $207.3 million in short-term investments, and a $20 million milestone payment from Roche extending their cash runway. ...

Why has Sami Corwin rated poseida Therapeutics a buy?

Sami Corwin has given his Buy rating due to a combination of factors that highlight Poseida Therapeutics’ promising future. The recent milestone payment from Roche, which resulted from the nomination of a new dual-targeted CAR-T therapy, has extended Poseida’s financial runway into early 2026. ...